23 search results for: disease severity
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP
Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis
This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet, as well as current and emerging treatment options.
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet
This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet
Compounded Burden of Co-existing Type 2 Airway Diseases
In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.
Factors Associated With Development of Atopic Comorbidities in AD
Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.
Can early intervention modify the course of AD?
Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
In this educational presentation, Profs. Vibeke Backer and Sietze Reitsma cover key aspects of type 2 inflammation and its role in the pathogenesis and management of CRSwNP and practical strategies for optimizing disease control and improving patient outcomes.
Understanding IL-33: A Key Factor in COPD Pathogenesis
Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
Vibeke Backer and Prof. Sietze Reitsma contribute their insights. Crucially, the symposium will also focus on future directions, including emerging therapies, personalized medicine approaches, and innovative strategies aimed at achieving better disease control and improved patient outcomes in CRSwNP.
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
